학술논문
A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: Results from the 3-month double-blind treatment phase of the conquer study
Document Type
Abstract
Author
Source
In Journal of the Neurological Sciences 15 October 2019 405 Supplement:128-128
Subject
Language
ISSN
0022-510X